You do not have permission to edit this page, for the following reasons:

This IP address has been blocked from editing Wikipedia.
This does not affect your ability to read Wikipedia pages.
Most people who see this message have done nothing wrong. Some kinds of blocks restrict editing from specific service providers or telecom companies in response to recent abuse or vandalism, and can sometimes affect other users who are unrelated to that abuse. Review the information below for assistance if you do not believe that you have done anything wrong.

The IP address or range 44.195.0.0/16 has been blocked (disabled) by ‪Blablubbs‬ for the following reason(s):

The IP address that you are currently using has been blocked because it is believed to be a web host provider or colocation provider. To prevent abuse, web hosts and colocation providers may be blocked from editing Wikipedia.
You will not be able to edit Wikipedia using a web host or colocation provider because it hides your IP address, much like a proxy or VPN.
We recommend that you attempt to use another connection to edit. For example, if you use a proxy or VPN to connect to the internet, turn it off when editing Wikipedia. If you edit using a mobile connection, try using a Wi-Fi connection, and vice versa. If you are using a corporate internet connection, switch to a different Wi-Fi network. If you have a Wikipedia account, please log in.
If you do not have any other way to edit Wikipedia, you will need to request an IP block exemption.

How to appeal if you are confident that your connection does not use a colocation provider's IP address:
If you are confident that you are not using a web host, you may appeal this block by adding the following text on your talk page: ((unblock|reason=Caught by a colocation web host block but this host or IP is not a web host. My IP address is _______. Place any further information here. ~~~~)). You must fill in the blank with your IP address for this block to be investigated. Your IP address can be determined here. Alternatively, if you wish to keep your IP address private you can use the unblock ticket request system. There are several reasons you might be editing using the IP address of a web host or colocation provider (such as if you are using VPN software or a business network); please use this method of appeal only if you think your IP address is in fact not a web host or colocation provider.

Administrators: The IP block exemption user right should only be applied to allow users to edit using web host in exceptional circumstances, and requests should usually be directed to the functionaries team via email. If you intend to give the IPBE user right, a CheckUser needs to take a look at the account. This can be requested most easily at SPI Quick Checkuser Requests. Unblocking an IP or IP range with this template is highly discouraged without at least contacting the blocking administrator.

This block will expire on 09:46, 11 January 2025.

Even when blocked, you will usually still be able to edit your user talk page, as well as email administrators and other editors.

For information on how to proceed, please read the FAQ for blocked users and the guideline on block appeals. The guide to appealing blocks may also be helpful.

Other useful links: Blocking policy · Help:I have been blocked
Your IP address is in a range that has been blocked on all Wikimedia Foundation wikis. The block was made by ‪AntiCompositeNumber‬. The reason given is Open proxy/Webhost: Visit the FAQ if you are affected .
- Start of block: 13:55, 18 August 2022
- Expiry of block: 13:55, 18 January 2025
Your current IP address is 44.195.68.6. The blocked range is 44.195.0.0/16. Please include all above details in any queries you make. If you believe you were blocked by mistake, you can find additional information and instructions in the No open proxies global policy. Otherwise, to discuss the block please post a request for review on Meta-Wiki. You could also send an email to the stewards VRT queue at stewards@wikimedia.org including all above details.

You can view and copy the source of this page:

{| class="wikitable floatright mw-collapsible (({state<includeonly>|mw-collapsed</includeonly>))}" style="font-size:small; margin: 1em auto;"
|+ class="nowrap" | ((Navbar|Potencies and durations of natural estrogens by intramuscular injection|mini=y)) ((Font|size=104%|<noinclude>[[Potency (pharmacology)|Potencies]]</noinclude><includeonly>Potencies</includeonly> and <noinclude>[[duration of action|duration]]s</noinclude><includeonly>durations</includeonly> of <noinclude>[[bioidentical|natural]]</noinclude><includeonly>natural</includeonly> <noinclude>[[estrogen (medication)|estrogen]]s</noinclude><includeonly>estrogens</includeonly> by <noinclude>[[intramuscular injection]]</noinclude><includeonly>intramuscular injection</includeonly>))
|-
! rowspan="2" | Estrogen !! rowspan="2" | Form !! colspan="2" | Dose (mg) !! rowspan="2" | Duration by dose (mg) <noinclude> || rowspan="2" | Refs</noinclude>
|-
! ((abbr|EPD|Total endometrial proliferation dose over 14 days)) !! ((abbr|CICD|Once-monthly combined injectable contraceptive dose))
|-
| rowspan="4" | ((No selflink|Estradiol (medication)|Estradiol)) || Aq. soln. || ? || – || <1 d <noinclude> || <ref name="pmid14089314">((cite journal | vauthors = Davis ME, Wiener M, Jacobson HI, Jensen EV | title = Estradiol metabolism in pregnant and nonpregnant women | journal = American Journal of Obstetrics and Gynecology | volume = 87 | pages = 979–990 | date = December 1963 | issue = 8 | pmid = 14089314 | doi = 10.1016/0002-9378(63)90091-7 ))</ref></noinclude>
|-
| Oil soln. || 40–60 || – || 1–2 ≈ 1–2 d <noinclude> || <ref name="Howard1949">((cite book| vauthors = Howard ME |title=Modern Drug Encyclopedia and Therapeutic Index|url=https://books.google.com/books?id=ltlLAQAAMAAJ|year=1949|publisher=Drug Publications|page=322|quote=Supply: ALPHA ESTRADIOL, U.S.P. IN SESAME OIL—For intramuscular injection, 0.14 mg per cc, 0.28 mg per cc, and 0.7 mg per cc. Ampuls—1 cc—Boxes of 12, 25, 100. Vials, 30 cc—Boxes of 1, 6. (Chicago Pharmacal). ALPHA-ESTRADIOL, U.S.P. IN SUSPENSION—0.14 mg per cc, 0.28 mg per cc, and 0.7 mg per cc. Vials, 30 cc—Boxes of 1, 6. (Chicago Pharmacal).))</ref><ref name="Brown1957">((cite journal | vauthors = Brown JB | title = The relationship between urinary oestrogens and oestrogens produced in the body | journal = The Journal of Endocrinology | volume = 16 | issue = 2 | pages = 202–212 | date = December 1957 | pmid = 13491750 | doi = 10.1677/joe.0.0160202 ))</ref></noinclude>
|-
| Aq. susp. || ? || 3.5 || 0.5–2 ≈ 2–7 d; 3.5 ≈ >5 d <noinclude> || <ref name="Howard1949" /><ref name="OsolPratt1973">((cite book| vauthors = Osol A, Pratt R |title=The United States dispensatory |url=https://books.google.com/books?id=jQy0AAAAIAAJ |year=1973|publisher=Lippincott|isbn=978-0-397-55901-5|page=498|quote=The following dosages for estradiol in the form of aqueous suspension injected intramuscularly, or pellets implanted subcutaneously, are recommended by a leading maunfacturer: Menopausal syndrome.—In average cases, 1 mg. intramuscularly 2 or 3 times weekly for 2 or 3 weeks; in more severe cases, 1 to 1.5 mg. Thereafter dosage is reduced to the minimum requirement, usually within the range of 0.5 to 1 mg. of estradiol twice weekly.))</ref><ref name="pmid14771156">((cite journal | vauthors = Newman GT | title = Estrogen therapy by implantation of estradiol crystals | journal = American Journal of Obstetrics and Gynecology | volume = 60 | issue = 3 | pages = 661–664 | date = September 1950 | pmid = 14771156 | doi = 10.1016/0002-9378(50)90438-8 ))</ref><ref name="pmid122429">((cite journal | vauthors = Jones TM, Fang VS, Landau RL, Rosenfield R | title = Direct inhibition of Leydig cell function by estradiol | journal = The Journal of Clinical Endocrinology and Metabolism | volume = 47 | issue = 6 | pages = 1368–1373 | date = December 1978 | pmid = 122429 | doi = 10.1210/jcem-47-6-1368 ))</ref><ref name="YanPan1987">((cite journal | vauthors = Yan Y, Pan J, Zhang Y, Kang J | title = The effect of monthly injectable contraceptive megestrol acetate compound on pituitary-ovarian function | journal = Journal of Shanghai Second Medical University | year = 1987 | issue = 2 | pages = 7–12 | issn = 1001-6686 | url = http://new.oversea.cnki.net/KCMS/detail/detail.aspx?dbcode=CJFD&filename=SHEI198702001))</ref></noinclude>
|-
| Microsph. || ? || – || 1 ≈ 30 d <noinclude> || <ref name="PLM">((cite web | url = http://www.serviciosplm.com/micrositios/fsimilares/Home/DrugDetail?divisionId=%2035&categoryId=%20101&productId=%2054291&pharmaFormId=%20194 | title = Juvenum E (estradiol) – Medicamentos PLM | archive-url = https://web.archive.org/web/20180918012224/http://www.serviciosplm.com/micrositios/fsimilares/Home/DrugDetail?divisionId=%2035&categoryId=%20101&productId=%2054291&pharmaFormId=%20194 | archive-date = 18 September 2018 | website = Medicamentos PLM  | access-date = 17 September 2018))</ref><ref name="Espino y SosaCortés Fuentes2019">((cite book| vauthors = Espino y Sosa S, Cortés Fuentes M, Alejandro Gómez Rico J, Cortés Bonilla M |chapter=Non-polymeric Microspheres for the Therapeutic Use of Estrogens: An Innovative Technology |year=2019 |title=Estrogen | veditors = Khan WA |isbn=978-1-83880-867-9))</ref></noinclude>
|-
| rowspan="3" | ((No selflink|Estradiol benzoate)) || Oil soln. || 25–35 || – || 1.66 ≈ 2–3 d; 5 ≈ 3–6 d <noinclude> || <ref name="Reifenstein1944" /><ref name="pmid7389356">((cite journal | vauthors = Oriowo MA, Landgren BM, Stenström B, Diczfalusy E | title = A comparison of the pharmacokinetic properties of three estradiol esters | journal = Contraception | volume = 21 | issue = 4 | pages = 415–424 | date = April 1980 | pmid = 7389356 | doi = 10.1016/S0010-7824(80)80018-7 ))</ref></noinclude>
|-
| Aq. susp. || 20 || – || 10 ≈ 16–21 d <noinclude> || <ref name="pmid13750804">((cite journal | vauthors = Kaiser R | title = [Estrogen excretion during the cycle and after injection of estradiol esters. A contribution to therapy with depot estrogens] | language = de | journal = Geburtshilfe und Frauenheilkunde | volume = 21 | pages = 868–878 | date = September 1961 | pmid = 13750804 | trans-title = Estrogen excretion during the cycle and after injection of estradiol esters. A contribution to therapy with depot estrogens ))</ref><ref name="Kaiser1962">((cite book | vauthors = Kaiser R | chapter = Über die Oestrogenausscheidung nach Injektion von Oestradiolestern | trans-chapter = Estrogen excretion after injection of estradiol esters | pages = 227–232 | doi = 10.1007/978-3-642-86860-3_24 | title = Gewebs-und Neurohormone: Physiologie des Melanophorenhormons | trans-title = Tissue and Neurohormones: Physiology of the Melanophore Hormone | language = de | year = 1962 | publisher = Springer, Berlin, Heidelberg | isbn = 978-3-540-02909-0))</ref><!--<ref name="Toppozada1950">((cite journal | vauthors = Toppozada HK | title = Oestrogenic Therapy with Prolonged Action | journal = Obstetrical & Gynecological Survey | volume = 5 | issue = 4 | year = 1950 | pages = 531 | issn = 0029-7828 | doi = 10.1097/00006254-195008000-00021))</ref>--><ref name="Kahr2013" /></noinclude>
|-
| Emulsion || ? || – || 10 ≈ 14–21 d <noinclude> || <ref name="Kahr2013">((cite book| vauthors = Kahr H |title=Konservative Therapie der Frauenkrankheiten: Anzeigen, Grenzen und Methoden Einschliesslich der Rezeptur|url=https://books.google.com/books?id=Hte1BgAAQBAJ&pg=PA20|date=8 March 2013|publisher=Springer-Verlag|isbn=978-3-7091-5694-0|pages=20–))</ref><ref name="pmid14907837">((cite journal | vauthors = Ferin J | title = Relative duration of action of natural and synthetic estrogens administered parenterally in women with estrogen deficiency | journal = The Journal of Clinical Endocrinology and Metabolism | volume = 12 | issue = 1 | pages = 28–35 | date = January 1952 | pmid = 14907837 | doi = 10.1210/jcem-12-1-28 ))</ref></noinclude>
|-
| ((No selflink|Estradiol dipropionate)) || Oil soln. || 25–30 || – || 5 ≈ 5–8 d <noinclude> || <ref name="Reifenstein1944">((cite journal| vauthors = Reifenstein EC |title= Endocrinology: A Synopsis of Normal and Pathologic Physiology, Diagnostic Procedures, and Therapy|journal=Medical Clinics of North America|volume=28|issue=5|year=1944|pages=1232–1276|issn=0025-7125|doi=10.1016/S0025-7125(16)36180-6))</ref></noinclude>
|-
| ((No selflink|Estradiol valerate)) || Oil soln. || 20–30 || 5 || style="font-size: 88%" | 5 ≈ 7–8 d; 10 ≈ 10–14 d;<br />40 ≈ 14–21 d; 100 ≈ 21–28 d <noinclude> || <ref name="pmid7389356" /><ref name="Schneider1957">((cite thesis | vauthors = Schneider HG | title = Über Aufbau-und Erhaltungsdosis von Östradiolvalerianat | trans-title = About Build-Up and Maintenance Dose of Estradiol Valerate | language = de | publisher = Humboldt-Universität [Humboldt University] | location = Berlin, Germany | oclc = 831117167 | url = https://scholar.google.com/scholar?&cluster=6978952621467357023))</ref></noinclude>
|-
| ((No selflink|Estradiol benzoate butyrate|Estradiol benz. butyrate)) || Oil soln. || ? || 10 || 10 ≈ 21 d <noinclude> || <ref name="pmid865726">((cite journal | vauthors = Toppozada M | title = The clinical use of monthly injectable contraceptive preparations | journal = Obstetrical & Gynecological Survey | volume = 32 | issue = 6 | pages = 335–347 | date = June 1977 | pmid = 865726 | doi = 10.1097/00006254-197706000-00001 ))</ref><ref name="Toppozada1983">((cite book | vauthors = Toppozada MK | chapter = Monthly Injectable Contraceptives | pages = 93–103 | veditors = Goldsmith A, Toppozada M | title = Long-Acting Contraception | year = 1983 | oclc = 35018604 | url = https://scholar.google.com/scholar?cluster=14664537528797672080))</ref></noinclude>
|-
| rowspan="2" | ((No selflink|Estradiol cypionate)) || Oil soln. || 20–30 || – || 5 ≈ 11–14 d <noinclude> || <ref name="pmid7389356" /></noinclude>
|-
| Aq. susp. || ? || 5 || 5 ≈ 14–24 d <noinclude> || <ref name="pmid23265980">((cite journal | vauthors = Thurman A, Kimble T, Hall P, Schwartz JL, Archer DF | title = Medroxyprogesterone acetate and estradiol cypionate injectable suspension (Cyclofem) monthly contraceptive injection: steady-state pharmacokinetics | journal = Contraception | volume = 87 | issue = 6 | pages = 738–743 | date = June 2013 | pmid = 23265980 | doi = 10.1016/j.contraception.2012.11.010 ))</ref><ref name="RahimyRyan1999">((cite journal| vauthors = Rahimy MH, Ryan K, Hopkins NK |title=Lunelle™ monthly contraceptive injection (medroxyprogesterone acetate and estradiol cypionate injectable suspension): steady-state pharmacokinetics of MPA and E2 in surgically sterile women|journal=Contraception|volume=60|issue=4|year=1999|pages=209–214|issn=0010-7824|doi=10.1016/S0010-7824(99)00086-4|pmid=10640167 ))</ref><ref name="pmid30947128">((cite journal | vauthors = Martins RS, Antunes NJ, Comerlatti G, Caraccio G, Moreno RA, Frecentese F, Caliendo G, De Nucci G | display-authors = 6 | title = Quantification of estradiol cypionate in plasma by liquid chromatography coupled with tandem mass spectrometry: Application in a pharmacokinetic study in healthy female volunteers | journal = Journal of Pharmaceutical and Biomedical Analysis | volume = 170 | pages = 273–278 | date = June 2019 | pmid = 30947128 | doi = 10.1016/j.jpba.2019.03.053 | s2cid = 96433789 ))</ref></noinclude>
|-
| ((No selflink|Estradiol enanthate)) || Oil soln. || ? || 5–10 || 10 ≈ 20–30 d <noinclude> || <ref name="pmid3814225">((cite journal | vauthors = Wiemeyer JC, Fernandez M, Moguilevsky JA, Sagasta CL | title = Pharmacokinetic studies of estradiol enantate in menopausic women | journal = Arzneimittel-Forschung | volume = 36 | issue = 11 | pages = 1674–1677 | date = November 1986 | pmid = 3814225 ))</ref><ref name="pmid3769482">((cite journal | vauthors = Recio R, Garza-Flores J, Schiavon R, Reyes A, Diaz-Sanchez V, Valles V, Luz de la Cruz D, Oropeza G, Perez-Palacios G | display-authors = 6 | title = Pharmacodynamic assessment of dihydroxyprogesterone acetophenide plus estradiol enanthate as a monthly injectable contraceptive | journal = Contraception | volume = 33 | issue = 6 | pages = 579–589 | date = June 1986 | pmid = 3769482 | doi = 10.1016/0010-7824(86)90046-6 ))</ref><ref name="GualPérez-Palacios1973">((cite journal| vauthors = Gual C, Pérez-Palacios G, Perez AE, Ruiz MR, Solis J, Cervantes A, Iramain C, Schreiber EC | display-authors = 6 |title=Metabolic fate of a long-acting injectable estrogen-progestogen contraceptive 1,2|journal=Contraception|volume=7|issue=4|year=1973|pages=271–287|issn=0010-7824|doi=10.1016/0010-7824(73)90145-5))</ref></noinclude>
|-
| ((No selflink|Estradiol dienanthate)) || Oil soln. || ? || – || 7.5 ≈ >40 d <noinclude> || <ref name="SherwinGelfand1987">((cite journal | vauthors = Saygin D, Tabib T, Bittar HE, Valenzi E, Sembrat J, Chan SY, Rojas M, Lafyatis R | display-authors = 6 | title = Transcriptional profiling of lung cell populations in idiopathic pulmonary arterial hypertension | journal = Pulmonary Circulation | volume = 10 | issue = 1 | pages = 121–131 | year = 1987 | pmid = 32166015 | doi = 10.3109/01674828709016773 | pmc = 7052475 ))</ref><ref name="pmid3826177">((cite journal | vauthors = Sherwin BB, Gelfand MM, Schucher R, Gabor J | title = Postmenopausal estrogen and androgen replacement and lipoprotein lipid concentrations | journal = American Journal of Obstetrics and Gynecology | volume = 156 | issue = 2 | pages = 414–419 | date = February 1987 | pmid = 3826177 | doi = 10.1016/0002-9378(87)90295-X ))</ref></noinclude>
|-
| ((No selflink|Estradiol undecylate)) || Oil soln. || ? || – || 10–20 ≈ 40–60 d;<br />25–50 ≈ 60–120 d <noinclude> || <ref name="pmid13142295">((cite journal | vauthors = Wied GL | title = [Estradiol valerate and estradiol undecylate, two new estrogens with prolonged action; comparison with estradiol benzoate] | language = de | journal = Geburtshilfe und Frauenheilkunde | volume = 14 | issue = 1 | pages = 45–52 | date = January 1954 | pmid = 13142295 | trans-title = Estradiol valerate and estradiol undecylate, two new estrogens with prolonged action; comparison with estradiol benzoate ))</ref><ref name="pmid13391788">((cite journal | vauthors = Gouygou C, Gueritee N, Pye A | title = [A fat-soluble, delayed estrogen : the estradiol undecylate] | language = fr | journal = Therapie | volume = 11 | issue = 5 | pages = 909–917 | year = 1956 | pmid = 13391788 | trans-title = A fat-soluble, delayed estrogen: the estradiol undecylate ))</ref></noinclude>
|-
| ((No selflink|Polyestradiol phosphate)) || Aq. soln. || 40–60 || – || 40 ≈ 30 d; 80 ≈ 60 d;<br />160 ≈ 120 d <noinclude> || <ref name="BrambillaBerczeller1961">((cite journal | vauthors = Saygin D, Tabib T, Bittar HE, Valenzi E, Sembrat J, Chan SY, Rojas M, Lafyatis R | display-authors = 6 | title = Transcriptional profiling of lung cell populations in idiopathic pulmonary arterial hypertension | journal = Pulmonary Circulation | volume = 10 | issue = 1 | pages = 115–118 | year = 1961 | pmid = 32166015 | doi = 10.1177/2045894020908782 | pmc = 7052475 ))</ref><ref name="pmid8610057">((cite journal | vauthors = Stege R, Gunnarsson PO, Johansson CJ, Olsson P, Pousette A, Carlström K | title = Pharmacokinetics and testosterone suppression of a single dose of polyestradiol phosphate (Estradurin) in prostatic cancer patients | journal = The Prostate | volume = 28 | issue = 5 | pages = 307–310 | date = May 1996 | pmid = 8610057 | doi = 10.1002/(SICI)1097-0045(199605)28:5<307::AID-PROS6>3.0.CO;2-8 | s2cid = 33548251 ))</ref></noinclude>
|-
| rowspan="2" | ((No selflink|Estrone (medication)|Estrone)) || Oil soln. || ? || – || 1–2 ≈ 2–3 d <noinclude> || <ref name="Brown1957" /><ref name="Eisfelder1942">((cite journal | vauthors = Saygin D, Tabib T, Bittar HE, Valenzi E, Sembrat J, Chan SY, Rojas M, Lafyatis R | display-authors = 6 | title = Transcriptional profiling of lung cell populations in idiopathic pulmonary arterial hypertension | journal = Pulmonary Circulation | volume = 10 | issue = 1 | pages = 628–632 | year = 1942 | pmid = 32166015 | doi = 10.1210/jcem-2-11-628 | pmc = 7052475 ))</ref></noinclude>
|-
| Aq. susp. || ? || – || 0.1–2 ≈ 2–7 d <noinclude> || <ref name="Micromedex2003">((cite book|author=Micromedex|title=USP DI 2003: Drug Information for Healthcare Professionals|url=https://books.google.com/books?id=zEzWtsVl-KgC|date=1 January 2003|publisher=Thomson Micromedex|isbn=978-1-56363-429-1|page=1246|quote=ESTRONE Parenteral Dosage Forms ESTRONE INJECTABLE SUSPENSION USP Usual adult dose Atrophic vaginitis or Menopausal (vasomotor) symptoms or Vulvar atrophy—Intramuscular, 100 to 500 mcg (0.1 to 0.5 mg) two or three times a week, cyclically or continuously as appropriate. Estrogen deficiency, due to ovariectomy or Female hypogonadism or Primary ovarian failure—Intramuscular, 100 mcg (0.1 mg) to 1 mg a week, administered as a single dose or in divided doses, cyclically or continuously. A few patients may need doses of up to 2 mg a week.))</ref></noinclude>
|-
| ((No selflink|Estriol (medication)|Estriol)) || Oil soln. || ? || – || 1–2 ≈ 1–4 d <noinclude> || <ref name="Brown1957" /><ref name="HeitheckerAedo1991">((cite journal | vauthors = Heithecker R, Aedo AR, Landgren BM, Cekan SZ | title = Plasma estriol levels after intramuscular injection of estriol and two of its esters | journal = Hormone Research | volume = 35 | issue = 6 | pages = 234–238 | year = 1991 | pmid = 1819548 | doi = 10.1159/000181911 ))</ref></noinclude>
|-
| ((No selflink|Polyestriol phosphate)) || Aq. soln. || ? || – || 50 ≈ 30 d; 80 ≈ 60 d <noinclude> || </noinclude>
|- class="sortbottom"

|- class="sortbottom"
| colspan="6" style="width: 1px; background-color:#eaecf0; text-align: center;" | ((hidden|header='''Notes and sources'''|content='''Notes:''' All [[aqueous suspension]]s are of [[microcrystalline]] [[particle size]]. [[Estradiol]] production during the [[menstrual cycle]] is 30–640&nbsp;µg/d (6.4–8.6&nbsp;mg total per month or cycle). The [[vagina]]l [[epithelium]] maturation dosage of [[estradiol benzoate]] or [[estradiol valerate]] has been reported as 5 to 7&nbsp;mg/week. An effective [[ovulation-inhibiting dose]] of [[estradiol undecylate]] is 20–30&nbsp;mg/month. '''Sources:''' <noinclude>''Main/General:'' <ref name="Lauritzen1988">((cite book | vauthors = Lauritzen C | chapter = Natürliche und Synthetische Sexualhormone – Biologische Grundlagen und Behandlungsprinzipien | pages = 229–306 <!-- Specific pages: 278, 279, 291, 295, 301 --> | trans-chapter = Natural and Synthetic Sexual Hormones – Biological Basis and Medical Treatment Principles | veditors = Schneider HP, Lauritzen C, Nieschlag E | title = Grundlagen und Klinik der Menschlichen Fortpflanzung | trans-title = Foundations and Clinic of Human Reproduction | language = de | year = 1988 | publisher = Walter de Gruyter | isbn = 978-3110109689 | oclc = 35483492 | url = https://books.google.com/books?id=v4HvAQAACAAJ))</ref><ref name="KnörrKnörr-Gärtner1982">((cite book| vauthors = Knörr K, Knörr-Gärtner H, Beller FK, Lauritzen C |title=Lehrbuch der Geburtshilfe und Gynäkologie: Physiologie und Pathologie der Reproduktion|trans-title=Textbook of Obstetrics and Gynecology: Physiology and Pathology of Reproduction|url=https://books.google.com/books?id=OjvMBgAAQBAJ&pg=PA508|year=1982|publisher=Springer-Verlag|isbn=978-3-662-00526-2|pages=508–))</ref><ref name="KnörrBeller1972">((cite book| vauthors = Knörr K, Beller FK, Lauritzen C |title=Lehrbuch der Gynäkologie |trans-title=Textbook of Gynecology |url=https://books.google.com/books?id=ACybBwAAQBAJ&pg=PA212 |year=1972|publisher=Springer-Verlag|isbn=978-3-662-00942-0|pages=212–213))</ref><ref name="Labhart1974">((cite book| vauthors = Labhart A |title=Clinical Endocrinology: Theory and Practice |url=https://books.google.com/books?id=DAgJCAAAQBAJ&pg=PA551 |year=1974|publisher=Springer Science & Business Media|isbn=978-3-642-96158-8|pages=551–553))</ref><ref name="HorskyPresl1981">((cite book | vauthors = Horský J, Presl J | chapter=Hormonal Treatment of Disorders of the Menstrual Cycle | pages = 309–332 | doi = 10.1007/978-94-009-8195-9_11 | veditors = Horsky J, Presl J | title = Ovarian Function and its Disorders: Diagnosis and Therapy | chapter-url = https://books.google.com/books?id=7IrpCAAAQBAJ&pg=PA310 | date = 1981 | publisher = Springer Science & Business Media | isbn = 978-94-009-8195-9))</ref><ref name="Ufer1978">((cite book | vauthors = Ufer J | chapter = Zur Therapeutischen Anwendung der Hormone | trans-chapter = For the Therapeutic Use of Hormones | pages = 93–113 | doi = 10.1515/9783110837131-013 | title = Hormontherapie in der Frauenheilkunde: Grundlagen und Praxis | trans-title = Hormonal Therapy in Gynecology: Principles and Practice | edition = 5th | language = de | date = 1 January 1978 | publisher = Walter de Gruyter | isbn = 978-3110066647 | oclc = 924728827 | url = https://books.google.com/books?id=nUK5DwAAQBAJ&pg=PA100))</ref><ref name="Ufer1969">((cite book| vauthors = Ufer J |title=The Principles and Practice of Hormone Therapy in Gynaecology and Obstetrics|url=https://books.google.com/books?id=G8VsAAAAMAAJ|year=1969|publisher=de Gruyter|pages=44,138|quote=Table: Composition: Oestradiol valerate. Preparation: Primogyn Depot. Form of application: i.m. Proliferation dose in mg: 20–30. Estimated duration of action following a single application in days: 12–14.))</ref><ref name="Pschyrembel1968">((cite book|author=Willibald Pschyrembel|title=Praktische Gynäkologie: für Studierende und Ärzte|trans-title=Practical Gynecology: for Students and Doctors |url= https://books.google.com/books?id=vVaTnHDFzZ0C&pg=PA598|date=1968 |publisher=Walter de Gruyter|isbn=978-3-11-150424-7|pages=598–599,601))</ref><ref name="pmid8013219">((cite journal | vauthors = Garza-Flores J | title = Pharmacokinetics of once-a-month injectable contraceptives | journal = Contraception | volume = 49 | issue = 4 | pages = 347–359 | date = April 1994 | pmid = 8013219 | doi = 10.1016/0010-7824(94)90032-9 ))</ref> ''Miscellaneous:'' <ref name="pmid6717863">((cite journal | vauthors = Nichols KC, Schenkel L, Benson H | title = 17 beta-estradiol for postmenopausal estrogen replacement therapy | journal = Obstetrical & Gynecological Survey | volume = 39 | issue = 4 | pages = 230–245 | date = April 1984 | pmid = 6717863 | doi = 10.1097/00006254-198404000-00022 ))</ref><!--E2 production rates--><ref name="Kaiser2008">((cite journal | vauthors = Kaiser R | title = [Gestagen-estrogen combinations in gynecology. On the history, dosage and use of a hormone principle] | journal = Geburtshilfe und Frauenheilkunde | volume = 53 | issue = 7 | pages = 503–513 | date = July 1993 | pmid = 8370495 | doi = 10.1055/s-2007-1022924 | trans-title = Gestagen-Oestrogen Combinations in Gynaecology. History, Dosage and Use of a Hormonal Principle ))</ref><!--EV and EB vaginal maturation dose--><ref name="pmid5008627">((cite journal | vauthors = el-Mahgoub S, Karim M | title = Depot estrogen as a monthly contraceptive in nulliparous women with mild uterine hypoplasia | journal = American Journal of Obstetrics and Gynecology | volume = 112 | issue = 4 | pages = 575–576 | date = February 1972 | pmid = 5008627 | doi = 10.1016/0002-9378(72)90319-5 ))</ref><!--EU ovulation-inhibiting dose--></noinclude><includeonly>See template.</includeonly>))
|}<!--

--><noinclude>((Documentation|content=
== See also ==
* [[Template:Parenteral potencies and durations of nonsteroidal estrogens]]
* [[Template:Oral potencies of estrogens]]
* [[Template:Parenteral potencies and durations of progestogens]]
* [[Template:Parenteral durations of androgens/anabolic steroids]]
* [[Template:Structural properties of selected estradiol esters]]
* [[Pharmacokinetics of estradiol#Intramuscular injection|Pharmacokinetics of estradiol § Intramuscular injection]]

== References ==
((Reflist))
))
[[Category:Medication templates]]
[[Category:Templates that generate named references]]
</noinclude>

Pages transcluded onto the current version of this page (help):

Estradiol (medication) (edit)
Estradiol benzoate (edit)
Estradiol benzoate butyrate (edit)
Estradiol cypionate (edit)
Estradiol dienanthate (edit)
Estradiol dipropionate (edit)
Estradiol enanthate (edit)
Estradiol undecylate (edit)
Estradiol valerate (edit)
Estriol (medication) (edit)
Estrone (medication) (edit)
Polyestradiol phosphate (edit)
Polyestriol phosphate (edit)
Template:Abbr (view source) (protected)
Template:Cite book (view source) (protected)
Template:Cite journal (view source) (protected)
Template:Cite thesis (view source) (template editor protected)
Template:Cite web (view source) (protected)
Template:Documentation (view source) (template editor protected)
Template:Font (view source) (template editor protected)
Template:Hidden (view source) (template editor protected)
Template:Hidden begin (view source) (template editor protected)
Template:Hidden begin/styles.css (view source) (template editor protected)
Template:Hidden end (view source) (template editor protected)
Template:Hlist/styles.css (view source) (protected)
Template:Main other (view source) (protected)
Template:Navbar (view source) (protected)
Template:No self link (view source) (semi-protected)
Template:No selflink (view source) (semi-protected)
Template:Reflist (view source) (protected)
Template:Reflist/styles.css (view source) (protected)
Module:Arguments (view source) (protected)
Module:Check for unknown parameters (view source) (protected)
Module:Citation/CS1 (view source) (protected)
Module:Citation/CS1/COinS (view source) (protected)
Module:Citation/CS1/Configuration (view source) (protected)
Module:Citation/CS1/Date validation (view source) (protected)
Module:Citation/CS1/Identifiers (view source) (protected)
Module:Citation/CS1/Utilities (view source) (protected)
Module:Citation/CS1/Whitelist (view source) (protected)
Module:Citation/CS1/styles.css (view source) (protected)
Module:Documentation (view source) (template editor protected)
Module:Documentation/config (view source) (template editor protected)
Module:Documentation/styles.css (view source) (template editor protected)
Module:Navbar (view source) (protected)
Module:Navbar/configuration (view source) (protected)
Module:Navbar/styles.css (view source) (protected)
Module:Redirect (view source) (protected)
Module:String (view source) (protected)

Return to Template:Potencies and durations of natural estrogens by intramuscular injection.

Retrieved from "https://en.wikipedia.org/wiki/Template:Potencies_and_durations_of_natural_estrogens_by_intramuscular_injection"